

3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Cortado Ventures Fund II-A | November 2022 | Indefinite | $3.3M | 10 |
| Cortado Ventures Fund II OZ | June 2022 | Indefinite | $507,000 | 3 |
| CORTADO VENTURES FUND II | 2022 | $21M | $10M | 94 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Michael Moradi-Araghi | Slowing | None listed | 1 | 1 |
| Nathaniel Harding | Slowing | Enterprise software | 2 | 1 |
| David Woods | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Too few companies classified yet to infer a focus. 1 of 3 portfolio companies are classified.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Cortado Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Mercury Fund | 1 | ABXR Labs |
| MPM BioVentures | 1 | MOAT BIOTECHNOLOGY |
A shared board seat: a company where filings name a Cortado Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.